Ascorbic Acid Supplementation Improves Postprandial Glucose and Blood Pressure in People with Type 2 Diabetes

Objectives. The aim of this study was to evaluate the prevalence and the risk factors of prolonged QTc interval among Chinese patients with type 2 diabetes.Methods. The retrospective study included 3156 outpatients from the Diabetes Centre, the 306th Hospital of PLA, during the period from September 2003 to June 2010. QT interval was measured manually in the 12-lead conventional electrocardiogram. The QT interval corrected for heart rate (QTc) was calculated using Bazett’s formula. Additional demographic and laboratory data were also collected. Potential risk factors of prolonged QTc interval were assessed using multivariable regression.Results.The prevalence of prolonged QTc interval among Chinese patients with type 2 diabetes was 30.1%. Height (OR 0.156, 95% CI 0.032~0.748), waist circumference (OR 1.025, 95% CI 1.010~1.040), diastolic blood pressure (OR 1.016, 95% CI 1.007~1.026), postprandial glucose (OR 1.040, 95% CI 1.022~1.059), fasting insulin (OR 1.014, 95% CI 1.003~1.025), and presence of microalbuminuria (OR 1.266, 95% CI 1.033~1.551) were significant risk factors.Conclusions. The prevalence of prolonged QTc interval among Chinese patients with type 2 diabetes is high. Risk factors for prolongation of QTc interval were low height, high waist circumference, increasing diastolic blood pressure levels, high postprandial glucose levels, high fasting insulin levels, and presence of microalbuminuria.

Download Full-text

Effect of ascorbic acid supplementation on nitric oxide metabolites and systolic blood pressure in rats exposed to lead

Toxicology Letters ◽

10.1016/j.toxlet.2008.06.660 ◽

2008 ◽

Vol 180 ◽

pp. S36

Author(s):

Ali Khoshbaten ◽

Alireza Asgari ◽

Ali Norooz zadeh ◽

Mohammad Amani

Keyword(s):

Nitric Oxide ◽

Blood Pressure ◽

Ascorbic Acid ◽

Systolic Blood Pressure ◽

Acid Supplementation ◽

Nitric Oxide Metabolites ◽

Ascorbic Acid Supplementation

Download Full-text

Oral Hypoglycemic Agent and Ascorbic Acid Supplementation Therapy Synergistically Ameliorates Blood Glucose, Serum Lipid and Inflammatory Response in Type 2 Diabetes Mellitus Patients

Journal of Analytical & Pharmaceutical Research ◽

10.15406/japlr.2016.03.00063 ◽

2016 ◽

Vol 3 (4) ◽

Author(s):

Okafor HK ◽

Ofoegbu AC ◽

Nlebedim AO

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Ascorbic Acid ◽

Type 2 Diabetes Mellitus ◽

Blood Glucose ◽

Inflammatory Response ◽

Serum Lipid ◽

Hypoglycemic Agent ◽

Ascorbic Acid Supplementation

Download Full-text

Abstract 11267: LX4211, a Dual Inhibitor of Sodium-Glucose Cotransporters 1 and 2, Reduces Systolic Blood Pressure in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment

Circulation ◽

10.1161/circ.130.suppl_2.11267 ◽

2014 ◽

Vol 130 (suppl_2) ◽

Author(s):

Pablo Lapuerta ◽

Paul Strumph ◽

Philip Banks ◽

Ikenna Ogbaa ◽

Brian Zambrowicz ◽

...

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Renal Impairment ◽

Systolic Blood Pressure ◽

Severe Renal Impairment ◽

Postprandial Glucose ◽

Dual Inhibitor

Introduction: Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors target only the kidney, and they have reduced efficacy when patients with type 2 diabetes mellitus (T2DM) have renal impairment (RI). LX4211 blocks sodium and glucose absorption in the gastrointestinal tract by inhibition of SGLT1, and it enhances urinary sodium and glucose excretion in the urine through inhibition of SGLT2. The dual SGLT1/2 action of LX4211 was anticipated to reduce systolic blood pressure (SBP) in addition to improving glucose control in the setting of RI. Methods: This analysis explored the effect of LX4211 on SBP in a clinical trial of patients with T2DM and moderate to severe RI. Patients (N=31) were randomly assigned to be treated with LX4211 (400 mg, N=16) or placebo (N=15) qd for 7 consecutive days. Postprandial glucose levels after a standard high glucose meal served as the primary measure of pharmacodynamic activity. Baseline and Day 8 trough SBP measures were each an average of 3 seated assessments. Results: Mean baseline characteristics included age 66.4 years, estimated glomerular filtration rate (eGFR) 43.4 mL/min/1.73 m 2 , and SBP 130.9 mmHg. Postprandial glucose area under the curve (sampled from pre-dose to 4 hours post meal) was reduced from Baseline to Day 7 by 169.3 mg*hr/dL on LX4211 compared to placebo (p=0.003). Day 8 SBP reductions were 11.4 mmHg on LX4211 and 0.0 mmHg on placebo (p=0.045 for difference between groups). Patients with greater RI (eGFR <45 mL/min/1.73 m2) treated with LX4211 (N=6) had a 10.5 mmHg SBP reduction compared to 0.3 mmHg on placebo (N=9). The difference between seated and standing SBP did not change with LX4211 (0.0 mmHg change, Day 8 vs. Baseline). There were no reports of hypotension, hypovolemia, no serious adverse events, and no patient discontinued due to an adverse event. Mild hypoglycemia was reported in 1 LX4211 patient compared to 2 placebo patients. Conclusions: LX4211 may reduce SBP and enhance glycemic control in T2DM patients with moderate to severe RI.

Download Full-text